Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2014  |  Volume : 10  |  Issue : 8  |  Page : 267--271

Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence


Cuiping Xu1, Jian Xie1, Ning Liang1, Junrong Wang2, Lili Qiao1, Hui Luo3, Jing Xin Zhang3, Jiandong Zhang1 
1 Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, China
2 Department of Immunization Program, Shizhong Center for Disease Control and Prevention, Jinan, China
3 Department of Graduate, Division of Oncology, Weifang Medical College, Weifang, China

Correspondence Address:
Jiandong Zhang
Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, 16766 Jingshi Road, Jinan, Shandong 250014
China

Purpose: The aim of this study was to retrospectively observe gastric adenocarcinoma patients with postoperative oligometastatic recurrence and investigated the effects of concurrent involved-field radiotherapy (RT) and XELOX on progression-free survival (PFS). Patients and Methods: From 2008 to 2011, 246 patients underwent curative resection of gastric carcinoma was enrolled. A retrospective review was performed on 34 patients with distant recurrence. Among them, 19 patients were oligometastases patients, where 13 patients received involved-field RT with a dose of 40-60 Gy by an intensity-modulated RT technique and concurrent XELOX chemotherapy, four patients were treated with XELOX chemotherapy alone (oxaliplatin 130 mg/m 2 , capecitabine 1000 mg/m 2 , twice daily, 3 week each cycle), and two patients with only brain metastasis were not included in the analysis. Results: The median PFS was 11 months in the 13 oligometastatic patients who received concurrent involved-field RT and XELOX. The oligometastatic patients receiving concurrent radiochemotherapy trended toward a better median PFS when compared with those receiving chemotherapy alone. Conclusions: For patients with postoperative oligometastatic recurrence, concurrent involved-field RT and XELOX showed better responses and was a choice for first-line treatment.


How to cite this article:
Xu C, Xie J, Liang N, Wang J, Qiao L, Luo H, Zhang JX, Zhang J. Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence.J Can Res Ther 2014;10:267-271


How to cite this URL:
Xu C, Xie J, Liang N, Wang J, Qiao L, Luo H, Zhang JX, Zhang J. Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence. J Can Res Ther [serial online] 2014 [cited 2020 Nov 25 ];10:267-271
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2014;volume=10;issue=8;spage=267;epage=271;aulast=Xu;type=0